# Q/C Technologies, Inc.: financial statements, quarterly

QCLS · Nasdaq · CIK 1321834 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/qcls.md) · [Financials](/companies/qcls/financials.md) · [Filings](/companies/qcls/filings.md) · [Insiders](/companies/qcls/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/qcls/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [1,912](/filings/0001493152-24-046026.md) | [2,961 d](/filings/0001641172-25-003814.md) | [1,199](/filings/0001641172-25-010937.md) | [401](/filings/0001641172-25-024859.md) | [708](/filings/0001493152-25-024320.md) | [1,133 d](/filings/0001493152-26-016872.md) | [1,546](/filings/0001493152-26-023751.md) | [873](/filings/0001493152-26-037333.md) | [356](/filings/0001493152-25-024320.md) | [697 d](/filings/0001493152-26-016872.md) | [511](/filings/0001493152-26-023751.md) | [236](/filings/0001493152-26-037333.md) |
| Operating income | $k | [(3,843)](/filings/0001493152-24-046026.md) | [(4,909) d](/filings/0001641172-25-003814.md) | [(2,785)](/filings/0001641172-25-010937.md) | [(3,370)](/filings/0001641172-25-024859.md) | [(1,826)](/filings/0001493152-25-024320.md) | [(2,189) d](/filings/0001493152-26-016872.md) | [(2,472)](/filings/0001493152-26-023751.md) | [(1,873)](/filings/0001493152-26-037333.md) | [(1,789)](/filings/0001493152-25-024320.md) | [(3,714) d](/filings/0001493152-26-016872.md) | [(1,855)](/filings/0001493152-26-023751.md) | [(6,791)](/filings/0001493152-26-037333.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [4,043](/filings/0001493152-24-046026.md) | [(2,364) d](/filings/0001641172-25-003814.md) | [(9,800)](/filings/0001493152-25-024320.md) | [(9,566)](/filings/0001493152-25-024320.md) | [(1,929)](/filings/0001493152-25-024320.md) | [(2,064) d](/filings/0001493152-26-016872.md) | [(1,125)](/filings/0001493152-26-037333.md) | [(1,796)](/filings/0001493152-26-037333.md) | [(2,811)](/filings/0001493152-25-024320.md) | [(5,895) d](/filings/0001493152-26-016872.md) | [(1,243)](/filings/0001493152-26-037333.md) | [(6,616)](/filings/0001493152-26-037333.md) |
| Diluted EPS | $ per share | [0.37](/filings/0001493152-24-046026.md) | not reported | [(5.14)](/filings/0001641172-25-010937.md) | [(4.54)](/filings/0001641172-25-024859.md) | [(107.62)](/filings/0001493152-25-024320.md) | not reported | [(0.36)](/filings/0001493152-26-023751.md) | [(51.10)](/filings/0001493152-26-037333.md) | [(2.50)](/filings/0001493152-25-024320.md) | not reported | [(0.19)](/filings/0001493152-26-023751.md) | [(0.79)](/filings/0001493152-26-037333.md) |
| Basic EPS | $ per share | [1.84](/filings/0001493152-24-046026.md) | not reported | [(5.14)](/filings/0001641172-25-010937.md) | [(4.54)](/filings/0001641172-25-024859.md) | [(107.62)](/filings/0001493152-25-024320.md) | not reported | [(0.36)](/filings/0001493152-26-023751.md) | [(51.10)](/filings/0001493152-26-037333.md) | [(2.50)](/filings/0001493152-25-024320.md) | not reported | [(0.19)](/filings/0001493152-26-023751.md) | [(0.79)](/filings/0001493152-26-037333.md) |

- Revenue: not reported
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.3](/filings/0001493152-23-041328.md) | [2.7](/filings/0001641172-25-003814.md) | [0.2](/filings/0001493152-24-019976.md) | [0.5](/filings/0001493152-24-032940.md) | [1.2](/filings/0001493152-24-046026.md) | [0.2](/filings/0001493152-26-016872.md) | [0.1](/filings/0001641172-25-010937.md) | [0.2](/filings/0001641172-25-024859.md) | [6.9](/filings/0001493152-25-024320.md) | [1.0](/filings/0001493152-26-037333.md) | [1.1](/filings/0001493152-26-023751.md) | [0.3](/filings/0001493152-26-037333.md) |
| Current assets | $m | [9.7](/filings/0001493152-23-041328.md) | [5.8](/filings/0001641172-25-003814.md) | [2.5](/filings/0001493152-24-019976.md) | [14.4](/filings/0001493152-24-032940.md) | [12.0](/filings/0001493152-24-046026.md) | [9.4](/filings/0001493152-26-016872.md) | [6.8](/filings/0001641172-25-010937.md) | [5.2](/filings/0001641172-25-024859.md) | [11.1](/filings/0001493152-25-024320.md) | [16.6](/filings/0001493152-26-037333.md) | [13.7](/filings/0001493152-26-023751.md) | [11.7](/filings/0001493152-26-037333.md) |
| Total assets | $m | [21.8](/filings/0001493152-23-041328.md) | [17.9](/filings/0001641172-25-003814.md) | [14.5](/filings/0001493152-24-019976.md) | [26.4](/filings/0001493152-24-032940.md) | [24.0](/filings/0001493152-24-046026.md) | [21.4](/filings/0001493152-26-016872.md) | [18.8](/filings/0001641172-25-010937.md) | [17.2](/filings/0001641172-25-024859.md) | [37.2](/filings/0001493152-25-024320.md) | [41.2](/filings/0001493152-26-037333.md) | [38.3](/filings/0001493152-26-023751.md) | [22.9](/filings/0001493152-26-037333.md) |
| Current liabilities | $m | [5.7](/filings/0001493152-23-041328.md) | [5.0](/filings/0001641172-25-003814.md) | [4.0](/filings/0001493152-24-019976.md) | [5.8](/filings/0001493152-24-032940.md) | [7.0](/filings/0001493152-24-046026.md) | [6.7](/filings/0001493152-26-016872.md) | [4.9](/filings/0001641172-25-010937.md) | [5.6](/filings/0001641172-25-024859.md) | [6.5](/filings/0001493152-25-024320.md) | [5.5](/filings/0001493152-26-037333.md) | [3.7](/filings/0001493152-26-023751.md) | [3.6](/filings/0001493152-26-037333.md) |
| Total liabilities | $m | [5.7](/filings/0001493152-23-041328.md) | [5.1](/filings/0001641172-25-003814.md) | [4.3](/filings/0001493152-24-019976.md) | [26.0](/filings/0001493152-24-032940.md) | [7.0](/filings/0001493152-24-046026.md) | [6.7](/filings/0001493152-26-016872.md) | [4.9](/filings/0001641172-25-010937.md) | [5.6](/filings/0001641172-25-024859.md) | [15.9](/filings/0001493152-25-024320.md) | [16.4](/filings/0001493152-26-037333.md) | [14.6](/filings/0001493152-26-023751.md) | [3.8](/filings/0001493152-26-037333.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [15.5](/filings/0001493152-24-046026.md) | [12.4](/filings/0001493152-26-016872.md) | [9.9](/filings/0001493152-25-024320.md) | [0.1](/filings/0001493152-24-032940.md) | [16.8](/filings/0001493152-25-024320.md) | [9.8](/filings/0001493152-26-037333.md) | [8.7](/filings/0001493152-26-037333.md) | [5.3](/filings/0001493152-26-037333.md) | [14.3](/filings/0001493152-25-024320.md) | [21.8](/filings/0001493152-26-037333.md) | [20.7](/filings/0001493152-26-037333.md) | [16.1](/filings/0001493152-26-037333.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,156) d](/filings/0001493152-24-046026.md) | [(1,933) d](/filings/0001641172-25-003814.md) | [(1,757)](/filings/0001641172-25-010937.md) | [(2,669) d](/filings/0001641172-25-024859.md) | [(2,430) d](/filings/0001493152-25-024320.md) | [(2,121) d](/filings/0001493152-26-016872.md) | [(2,640)](/filings/0001493152-26-023751.md) | [(2,065) d](/filings/0001493152-26-037333.md) | [(1,160) d](/filings/0001493152-25-024320.md) | [(3,200) d](/filings/0001493152-26-016872.md) | [(3,287)](/filings/0001493152-26-023751.md) | [(1,819) d](/filings/0001493152-26-037333.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $k | not reported | not reported | not reported | not reported | [68.1 d](/filings/0001493152-25-024320.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Dividends paid: us-gaap:PaymentsOfDividends

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [38.3](/filings/0001493152-23-028603.md) | [39.0](/filings/0001493152-23-041328.md) | [1.4](/filings/0001493152-24-032940.md) | [7.8](/filings/0001493152-24-046026.md) | [2.1](/filings/0001641172-25-010937.md) | [2.3](/filings/0001641172-25-024859.md) | [0.0](/filings/0001493152-25-024320.md) | [5.3](/filings/0001493152-26-023751.md) | [0.1](/filings/0001493152-26-037333.md) | [1.5](/filings/0001493152-25-024320.md) | [8.1](/filings/0001493152-26-023751.md) | [8.2](/filings/0001493152-26-037333.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 8,189,838 at 2026-08-12, from the cover of the [10-Q filed 2026-08-12](/filings/0001493152-26-037333.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.